11.12
0.00%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Egetis Therapeutics AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker EGTX.ST. It has been listed since 7 April 2011. In the fiscal year to 31 December 2025, it reported revenue of SEK 62.4m and a net loss of SEK 342.5m. At that date it held total assets of SEK 639.1m and shareholders' equity of SEK 338.7m.
Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Apr 2011
- Employees
- 25
- Website
- egetis.com ↗
Leadership
Pay as last reported
- Mr. Mats BlomIndependent Chairman of the BoardSEK 300,000
- Mr. Nicklas WesterholmChief Executive OfficerSEK 5.9m
- Mr. Yilmaz MahshidChief Financial Officer
- Ms. Anny BedardPresident of Egetis North America
- Dr. Katayoun Welin-BergerVice President - Technical Operations
- Mr. Karl HardVice President, Head - Investor Relations and Communications
- Mr. Henrik KrookVice President - Commercial Operations
- Mr. Christian SonessonVice President - Product Strategy and Development
- Mr. Nils HallenHuman Resources Manager
- Ms. Kristina NygrenChief Medical Officer
- Ms. Margarida DuarteIndependent Director
- Ms. Gunilla OsswaldIndependent DirectorSEK 200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Egetis Therapeutics AB's pipeline includes Emcitate for MCT8 deficiency treatment.
- PledOx targets nerve damage from chemotherapy, addressing a significant medical need.
- Aladote reduces acute liver injury risk from acetaminophen poisoning effectively.
Weaknesses
- The company has only 25 employees, limiting operational capacity.
- Egetis Therapeutics AB's IPO was in 2011, indicating limited recent market presence.
- Stockholm headquarters may restrict access to broader biotech talent pools.
Opportunities
- Expanding Emcitate's use for MCT8 deficiency could capture new markets.
- PledOx's application in chemotherapy could grow with rising cancer treatments.
- Aladote's market potential increases with acetaminophen usage worldwide.
Threats
- Biotechnology sector competition may impact Emcitate's market share.
- Regulatory hurdles could delay PledOx's approval process significantly.
- Aladote faces competition from existing liver injury treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.